Liposomal Compositions With Anti-Cancer Agents, Tumor-Targeting Lipopeptides
Summary
The USPTO published patent application US20260096988A1 on April 9, 2026, filed by inventors Debabrata Mukhopadhyay, Vijay S. Madamsetty, and Krishnendu Pal. The application covers liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides, as well as nanodiamond complexes and particles as carriers for anti-cancer agents.
This publication provides public notice of the intellectual property claims related to advanced drug delivery compositions for cancer treatment. The pharmaceutical and biotechnology industries should monitor this application for potential impacts on cancer therapeutics development.
What changed
The USPTO published patent application US20260096988A1 disclosing liposomal compositions containing anti-cancer agents combined with tumor-targeting lipopeptides. The compositions also include nanodiamond complexes and particles as carriers for anti-cancer drug delivery. The application covers various therapeutic compound classifications including A61K 9/1275 (liposomes) and A61P 35/00 (antineoplastic agents).
For pharmaceutical manufacturers and biotechnology companies developing targeted cancer therapies, this published application signals potential intellectual property claims in the liposomal drug delivery space. While patent applications do not create immediate compliance obligations, entities developing similar drug delivery technologies should monitor the prosecution of this application for potential freedom-to-operate considerations.
What to do next
- Monitor for updates
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
DRUG DELIVERY METHODS AND COMPOSITIONS
Application US20260096988A1 Kind: A1 Apr 09, 2026
Inventors
Debabrata Mukhopadhyay, Vijay S. Madamsetty, Krishnendu Pal
Abstract
The present application provides liposomal compositions containing anti-cancer agents and tumor-targeting lipopeptides. The present application also provides nanodiamond complexes and particles as carriers for anti-cancer agents
CPC Classifications
A61K 9/1275 A61K 31/165 A61K 31/337 A61K 31/343 A61K 31/353 A61K 31/365 A61K 31/381 A61K 31/433 A61K 31/436 A61K 31/444 A61K 31/475 A61K 31/513 A61K 31/517 A61K 31/519 A61K 31/52 A61K 31/5377 A61K 31/5545 A61K 31/7068 A61K 31/7072 A61K 31/7076 A61K 47/60 A61K 47/6923 A61P 1/18 A61P 35/00 C07K 7/06 C07K 14/001 C07K 16/2863 C07K 19/00
Filing Date
2025-11-17
Application No.
19391145
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.